RNA editing, genetic medicine, and biotechnology research by Korro Bio

  • Dmytro Kharkov
  • 28.05.2026
Korro Bio, Inc. identifies surge in healthcare burden from ammonia in hepatic encephalopathy
Korro Bio, Inc. has presented findings at #EASL2026 indicating that patients with hepatic encephalopathy experience increased healthcare utilization due to elevated ammonia levels. The ...
  • Ashutosh Sureka
  • 19.05.2026
Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein
Korro Bio, Inc. has designated KRRO-111 as its development candidate for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). In preclinical studies, KRRO-111 demonstrated greater ...
  • Eugene Komchuk
  • 16.05.2026
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage
Korro Bio, Inc. has announced meaningful progress with KRRO-121, its GalNAc-conjugated RNA editing oligonucleotide designed as a potential therapy for hyperammonemia, a dangerous build-up of ...